Penumbra Inc., the world’s leading thrombectomy company, has secured CE Mark for its SwiftPAC™ neuro embolisation coil, which is part of the Swift™ Coil System and is now commercially available in Europe.
Penumbra’s SwiftPAC coils are designed as a soft space-seeking “liquid metal” that conforms to the target vessel for dense packing. These attributes provide versatility across a variety of clinical applications.
“The shapeless design of the new SwiftPAC coil allows for efficient, dense occlusion of the MMA branches in awake patients and the essential control to avoid dangerous anastomoses,” said Johannes Hensler, MD, a senior physician at the University Hospital Schleswig-Holstein in Germany.
The innovative 2D sinusoidal shape is designed to help the coil break effortlessly to seek empty space. SwiftPAC is one of the softest 10-system coils on the market, with a softness value of .093.1 SwiftPAC coils offer physicians the ability to deploy and reposition with precision before detaching.
SwiftPAC has a .0135” primary diameter deliverable through .0165” microcatheters and is available in a range of lengths from 3 cm to 60 cm to optimise embolisation across vessel sizes and anatomy.
Important Safety Information
Additional information about Penumbra’s products can be located on Penumbra’s website at https://www.penumbrainc.com/eu/products/neuro-embolisation-system/. Product availability varies by country. Prior to use, please refer to Instructions for Use for complete product indications, contraindications, warnings, precautions, potential adverse events and detailed instructions for use. Risk information can be found at peninc.info/risk.
Copyright ©2025 Penumbra, Inc. All rights reserved. SwiftPAC, and Swift are registered trademarks or trademarks of Penumbra, Inc. in the USA and other countries. All other trademarks are the property of their respective owners.
1. Data on file at Penumbra Inc.
